Amyotrophic lateral sclerosis: A neurovascular disease

Brain Research

Volumn 1398, Issue , 2011, Pages 113-125

  Garbuzova Davis, Svitlana ^a   Rodrigues, Maria C O ^a,b   Hernandez Ontiveros, Diana G ^a   Louis, Michael K ^a   Willing, Alison E ^a   Borlongan, Cesario V ^a   Sanberg, Paul R ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amyotrophic lateral sclerosis; Blood brain barrier (BBB); Blood spinal cord barrier (BSCB); Impairment; Microvascular pathology

Indexed keywords

AQUAPORIN 4; BREAST CANCER RESISTANCE PROTEIN; CASPASE; COLLAGEN TYPE 4; CYCLIC AMP; CYCLOOXYGENASE 2; ENTACTIN; EVANS BLUE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GLUCOSE TRANSPORTER; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; LAMININ; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; OCCLUDIN; PEROXYNITRITE; PROTEIN KINASE C; PROTEIN ZO1; PROTEIN ZO2; PROTEOHEPARAN SULFATE; REACTIVE OXYGEN METABOLITE; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ACUTE HEART INFARCTION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BASEMENT MEMBRANE; BLOOD BRAIN BARRIER; BLOOD SPINAL CORD BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN ISCHEMIA; DISEASE MODEL; ELECTRON MICROSCOPY; HUMAN; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MEMBRANE TRANSPORT; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PARKINSON DISEASE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CEREBRAL ARTERIES; HUMANS;

ANIMALIA;

EID: 79958850046     PISSN: 00068993     EISSN: 00068993     Source Type: Journal    
DOI: 10.1016/j.brainres.2011.04.049     Document Type: Review

References (162)

1. Abbott, N., 2002. Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 200, 629-638. (Pubitemid 34823054)
2. Abbott, N.J., Romero, I.A., 1996. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today 2, 106-113.
3. Abbott, N.J., Ronnback, L., Hansson, E., 2006. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7, 41-53.
4. Abbott, N.J., Patabendige, A.A., Dolman, D.E., Yusof, S.R., Begley, D. J., 2010. Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13-25.
5. Agrawal, S., et al., 2006. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 203, 1007-1019.
6. Alexianu, M.E., Kozovska, M., Appel, S.H., 2001. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57, 1282-1289. (Pubitemid 32947389)
7. Almer, G., et al., 2001. Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann. Neurol. 49, 176-185.
8. Andreeva, A.Y., Krause, E., Muller, E.C., Blasig, I.E., Utepbergenov, D.I., 2001. Protein kinase C regulates the phosphorylation and cellular localization of occludin. J. Biol. Chem. 276, 38480-38486.
9. Annunziata, P., Volpi, N., 1985. High levels of C3c in the cerebrospinal fluid from amyotrophic lateral sclerosis patients. Acta Neurol. Scand. 72, 61-64.
10. Apostolski, S., et al., 1991. Serum and CSF immunological findings in ALS. Acta Neurol. Scand. 83, 96-98.
11. Arhart, R.W., 2010. A possible haemodynamic mechanism for amyotrophic lateral sclerosis. Med. Hypotheses 75, 341-346.
12. Armulik, A., et al., 2010. Pericytes regulate the blood-brain barrier. Nature 468, 557-561.
13. Avolio, C., et al., 2005. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult. Scler. 11, 441-446.
14. Ballabh, P., Braun, A., Nedergaard, M., 2004. The blood-brain barrier: an overview structure, regulation, and clinical implications. Neurobiol. Dis. 16, 1-13.
15. Banks, W.A., 2008. The blood-brain barrier. In: Ikezu, T., Gendelman, H.E. (Eds.), Neuroimmune Pharmacology.: Springer. New York, N. Y., pp. 21-38.
16. Bauer, H.C., Bauer, H., 2000. Neural induction of the blood-brain barrier: still an enigma. Cell. Mol. Neurobiol. 20, 13-28.
17. Bauer, A.T., Burgers, H.F., Rabie, T., Marti, H.H., 2010. Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. J. Cereb. Blood Flow Metab. 30, 837-848.
18. Bauer, H.C., et al., 2011. New aspects of the molecular constituents of tissue barriers. J. Neural Transm. 118, 7-21.
19. Bell, R.D., Zlokovic, B.V., 2009. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 118, 103-113.
20. Bernacki, J., Dobrowolska, A., Nierwinska, K., Malecki, A., 2008. Physiology and pharmacological role of the blood-brain barrier. Pharmacol. Rep. 60, 600-622.
21. Beuche, W., et al., 2000. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport 11, 3419-3422.
22. Bilic, E., et al., 2006. Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls. Eur. J. Neurol. 13, 1340-1345.
23. Blann, A.D., et al., 2005. Circulating endothelial cells. Biomarker of vascular disease. Thromb. Haemost. 93, 228-235.
24. Blecharz, K.G., et al., 2010. Glucocorticoid effects on endothelial barrier function in the murine brain endothelial cell line cEND incubated with sera from patients with multiple sclerosis. Mult. Scler. 16, 293-302.
25. Boillee, S., et al., 2006. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389-1392. (Pubitemid 43839552)
26. Bossolasco, P., et al., 2010. Metalloproteinase alterations in the bone marrow of ALS patients. J. Mol. Med. 88, 553-564.
27. Boston-Howes, W., et al., 2008. Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis. Exp. Neurol. 213, 229-237.
28. Bradbury, M.W., 1985. The blood-brain barrier. Transport across the cerebral endothelium. Circ. Res. 57, 213-222.
29. Bruijn, L.I., Miller, T.M., Cleveland, D.W., 2004. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27, 723-749.
30. Candelario-Jalil, E., Yang, Y., Rosenberg, G.A., 2009. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 158, 983-994.
31. Carman, C.V., Springer, T.A., 2008. Trans-cellular migration: cell-cell contacts get intimate. Curr. Opin. Cell Biol. 20, 533-540.
32. Chong, A.Y., Lip, G.Y., Freestone, B., Blann, A.D., 2006. Increased circulating endothelial cells in acute heart failure: comparison with von Willebrand factor and soluble E-selectin. Eur. J. Heart Fail. 8, 167-172.
33. Collins, N.T., et al., 2006. Cyclic strain-mediated regulation of vascular endothelial occludin and ZO-1: influence on intercellular tight junction assembly and function. Arterioscler. Thromb. Vasc. Biol. 26, 62-68.
34. Conner, M.T., Conner, A.C., Brown, J.E., Bill, R.M., 2010. Membrane trafficking of aquaporin 1 is mediated by protein kinase C via microtubules and regulated by tonicity. Biochemistry 49, 821-823.
35. Consilvio, C., Vincent, A.M., Feldman, E.L., 2004. Neuroinflammation, COX-2, and ALS - a dual role? Exp. Neurol. 187, 1-10.
36. Cookson, M.R., Shaw, P.J., 1999. Oxidative stress and motor neurone disease. Brain Pathol. 9, 165-186.
37. D'Amore, P.A., 1992. Mechanisms of endothelial growth control. Am. J. Respir. Cell Mol. Biol. 6, 1-8.
38. De Vries, H.E., Kuiper, J., de Boer, A.G., Van Berkel, T.J., Breimer, D. D., 1997. The blood-brain barrier in inflammatory disease. Pharmacol. Rev. 49, 143-155.
39. Demestre, M., Parkin-Smith, G., Petzold, A., Pullen, A.H., 2005. The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J. Neuroimmunol. 159, 146-154. (Pubitemid 40136512)
40. Dermietzel, R., Krause, D., 1991. Molecular anatomy of the blood-brain barrier as defined by immunocytochemistry. Int. Rev. Cytol. 127, 57-109.
41. Di Giovanni, S., et al., 2005. Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc. Natl. Acad. Sci. U. S.A. 102, 8333-8338.
42. Díaz-Flores, L., et al., 2009. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol. Histopathol. 24, 909-969.
43. Donnenfeld, H., Kascsak, R.J., Bartfeld, H., 1984. Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J. Neuroimmunol. 6, 51-57. (Pubitemid 14132684)
44. Du, D., et al., 2010. The tight junction protein, occludin, regulates the directional migration of epithelial cells. Dev. Cell 18, 52-63.
45. Duffy, H.S., John, G.R., Lee, S.C., Brosnan, C.F., Spray, D.C., 2000. Reciprocal regulation of the junctional proteins claudin-1 and connexin43 by interleukin-1beta in primary human fetal astrocytes. J. Neurosci. 20, RC114.
46. Elliott, J.L., 2001. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res. Mol. Brain Res. 95, 172-178.
47. Engelhardt, J.I., Appel, S.H., 1990. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch. Neurol. 47, 1210-1216.
48. Engelhardt, J.I., Tajti, J., Appel, S.H., 1993. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch. Neurol. 50, 30-36.
49. Engelhardt, J.I., Siklos, L., Komuves, L., Smith, R.G., Appel, S.H., 1995. Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons. Synapse 20, 185-199.
50. Fang, L., et al., 2009. Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS). J. Neurol. Sci. 285, 62-66.
51. Fang, L., et al., 2010. MMP-2 and MMP-9 are elevated in spinal cord and skin in a mouse model of ALS. J. Neurol. Sci. 294, 51-56.
52. 2 induces paracellular permeability of porcine brain-derived microvascular endothelial cells by activation of the p44/42 MAP kinase pathway. Eur. J. Cell Biol. 84, 687-697.
53. Fleegal, M.A., Hom, S., Borg, L.K., Davis, T.P., 2005. Activation of PKC modulates blood-brain barrier endothelial cell permeability changes induced by hypoxia and posthypoxic reoxygenation. Am. J. Physiol. Heart Circ. Physiol. 289, H2012-H2019.
54. Forster, C., 2008. Tight junctions and the modulation of barrier function in disease. Histochem. Cell Biol. 130, 55-70.
55. Fukuda, S., et al., 2004. Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 35, 998-1004. (Pubitemid 38419817)
56. Garbuzova-Davis, S., et al., 2007a. Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 1157, 126-137. (Pubitemid 46935078)
57. Garbuzova-Davis, S., et al., 2007b. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS One 2, e1205.
58. Garbuzova-Davis, S., Saporta, S., Sanberg, P.R., 2008. Implications of blood-brain barrier disruption in ALS. Amyotroph. Lateral Scler. 9, 375-376.
59. Garbuzova-Davis, S., et al., 2010. Reduction of circulating endothelial cells in peripheral blood of ALS patients. PLoS One 5, e10614.
60. Gasche, Y., Soccal, P.M., Kanemitsu, M., Copin, J.C., 2006. Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. Front. Biosci. 11, 1289-1301.
61. Guillemin, G.J., Brew, B.J., 2004. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and differentiation. J. Leukoc. Biol. 75, 388-397.
62. Hall, E.D., Oostveen, J.A., Gurney, M.E., 1998. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23, 249-256. (Pubitemid 28259722)
63. Haseloff, R.F., Blasig, I.E., Bauer, H.C., Bauer, H., 2005. In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro. Cell. Mol. Neurobiol. 25, 25-39.
64. Haverkamp, L.J., Appel, V., Appel, S.H., 1995. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 118, 707-719.
65. Hawkins, B.T., Davis, T.P., 2005. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 57, 173-185.
66. Hawkins, R.A., Peterson, D.R., Viña, J.R., 2002. The complementary membranes forming the blood-brain barrier. IUBMB Life 54, 101-107. (Pubitemid 35416728)
67. Henkel, J.S., et al., 2004. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 55, 221-235.
68. Henkel, J.S., Beers, D.R., Wen, S., Bowser, R., Appel, S.H., 2009. Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology 72, 1614-1616.
69. Hensley, K., et al., 2002. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J. Neurochem. 82, 365-374. (Pubitemid 34774627)
70. Hirschi, K.K., D'Amore, P.A., 1996. Pericytes in the microvasculature. Cardiovasc. Res. 32, 687-698.
71. Hurst, R.D., Fritz, I.B., 1996. Properties of an immortalised vascular endothelial/glioma cell co-culture model of the blood-brain barrier. J. Cell. Physiol. 167, 81-88.
72. Jung, J.E., et al., 2010. Reperfusion and neurovascular dysfunction in stroke: from basic mechanisms to potential strategies for neuroprotection. Mol. Neurobiol. 41, 172-179.
73. Kar, S., Subbaram, S., Carrico, P.M., Melendez, J.A., 2010. Redox-control of matrix metalloproteinase-1: a critical link between free radicals, matrix remodeling and degenerative disease. Respir. Physiol. Neurobiol. 174, 299-306.
74. Keller, J.N., et al., 1997. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 69, 273-284. (Pubitemid 27274182)
75. Kida, S., Steart, P.V., Zhang, E.T., Weller, R.O., 1993. Perivascular cells act as scavengers in the cerebral perivascular spaces and remain distinct from pericytes, microglia and macrophages. Acta Neuropathol. 85, 646-652. (Pubitemid 23212032)
76. Kirk, J., Plumb, J., Mirakhur, M., McQuaid, S., 2003. Tight junctional abnormality in multiple sclerosis white matter affects all calibers of vessel and is associated with blood-brain barrier leakage and active demyelination. J. Pathol. 201, 319-327. (Pubitemid 37258943)
77. Krizanac-Bengez, L., Hossain, M., Fazio, V., Mayberg, M., Janigro, D., 2006. Loss of flow induces leukocyte-mediated MMP/TIMP imbalance in dynamic in vitro blood-brain barrier model: role of pro-inflammatory cytokines. Am. J. Physiol. Cell Physiol. 291, C740-C749.
78. Kutcher, M.E., Herman, I.M., 2009. The pericyte: cellular regulator of microvascular blood flow. Microvasc. Res. 77, 235-246.
79. Lee, K.W., Lip, G.Y., Tayebjee, M., Foster, W., Blann, A.D., 2005. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 105, 526-532. (Pubitemid 40070731)
80. Lefauconnier, J.M., 1989. Transport processes through the blood-brain barrier. Reprod. Nutr. Dev. 29, 689-702.
81. Leonardi, A., Abbruzzese, G., Arata, L., Cocito, L., Vische, M., 1984. Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. J. Neurol. 231, 75-78. (Pubitemid 14137306)
82. Ley, K., Laudanna, C., Cybulsky, M.I., Nourshargh, S., 2007. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678-689.
83. Lindsberg, P.J., Strbian, D., Karjalainen-Lindsberg, M.L., 2010. Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage. J. Cereb. Blood Flow Metab. 30, 689-702.
84. Lorenzl, S., De Pasquale, G., Segal, A.Z., Beal, M.F., 2003a. Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia. Stroke 34, e37-e38.
85. Lorenzl, S., et al., 2003b. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J. Neurol. Sci. 207, 71-76.
86. Mantovani, A., Bussolino, F., Dejana, E., 1992. Cytokine regulation of endothelial cell function. FASEB 6, 2591-2599.
87. Matsumura, T., Wolff, K., Petzelbauer, P., 1997. Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin. J. Immunol. 158, 3408-3416. (Pubitemid 127484061)
88. Matter, K., Balda, M.S., 2003. Signalling to and from tight junctions. Nat. Rev. Mol. Cell Biol. 4, 225-236.
89. Mattson, M.P., 1997. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77, 1081-1132.
90. McGeer, P.L., McGeer, E.G., 2002. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26, 459-470.
91. Milane, A., et al., 2010. P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis. Neurosci. Lett. 472, 166-170.
92. Mitchell, J.D., Borasio, G.D., 2007. Amyotrophic lateral sclerosis. Lancet 369, 2031-2041.
93. Miyazaki, K., et al., 2011. Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J. Neurosci. Res. 89, 718-728.
94. Nadar, S.K., Lip, G.Y., Lee, K.W., Blann, A.D., 2005. Circulating endothelial cells in acute ischaemic stroke. Thromb. Haemost. 94, 707-712.
95. Nag, S., 2003. Morphology and molecular properties of cellular components of normal cerebral vessels. In: Nag, S. (Ed.), The Blood-brain Barrier: Biology and Research Protocols. Humana Press Inc., Totowa, NJ, pp. 3-36.
96. Nagasawa, K., et al., 2006. Possible involvement of gap junctions in the barrier function of tight junctions of brain and lung endothelial cells. J. Cell. Physiol. 208, 123-132.
97. Nakagawa, S., et al., 2007. Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell. Mol. Neurobiol. 27, 687-694.
98. Nakashima, I., et al., 2002. Redox-linked signal transduction pathways for protein tyrosine kinase activation. Antioxid. Redox Signal. 4, 517-531.
99. Nicaise, C., et al., 2009a. Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res. 1301, 152-162.
100. Nicaise, C., et al., 2009b. Aquaporin-4 overexpression in rat ALS model. Anat. Rec. (Hoboken) 292, 207-213.
101. Niebroj-Dobosz, I., Janik, P., Sokolowska, B., Kwiecinski, H., 2010. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 17, 226-231.
102. Nishioku, T., et al., 2010. Tumor necrosis factor-alpha mediates the blood-brain barrier dysfunction induced by activated microglia in mouse brain microvascular endothelial cells. J. Pharmacol. Sci. 112, 251-254.
103. Nuttall, R.K., et al., 2007. Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia. Glia 55, 516-526. (Pubitemid 46383181)
104. Ono, S., et al., 1998a. Decreased type IV collagen of skin and serum in patients with amyotrophic lateral sclerosis. Neurology 51, 114-120. (Pubitemid 28345369)
105. Ono, S., et al., 1998b. Collagen abnormalities in the spinal cord from patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 160, 140-147.
106. Ono, S., Imai, T., Shimizu, N., Nagao, K., 2000. Increased expression of laminin 1 in the skin of amyotrophic lateral sclerosis. Eur. Neurol. 43, 215-220.
107. Pardridge, W.M., 1986. Blood-brain barrier transport of nutrients. Fed. Proc. 45, 2047-2049.
108. Pardridge, W.M., 1999. Blood-brain barrier biology and methodology. J. Neurovirol. 5, 556-569. (Pubitemid 30032082)
109. Pasinelli, P., Brown, R.H., 2006. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci. 7, 710-723.
110. Petty, M.A., Lo, E.H., 2002. Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog. Neurobiol. 68, 311-323.
111. Pirttila, T., Vanhatalo, S., Turpeinen, U., Riikonen, R., 2004. Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS. Acta Neurol. Scand. 109, 337-341.
112. Polfliet, M.M., et al., 2001. Meningeal and perivascular macrophages of the central nervous system play a protective role during bacterial meningitis. J. Immunol. 167, 4644-4650. (Pubitemid 32954345)
113. Pozzi, A., Zent, R., 2009. Regulation of endothelial cell functions by basement membrane- and arachidonic acid-derived products. Wiley Interdiscip. Rev. Syst. Biol. Med. 1, 254-272.
114. Prat, A., Biernacki, K., Wosik, K., Antel, J.P., 2001. Glial cell influence on the human blood-brain barrier. Glia 36, 145-155. (Pubitemid 33055903)
115. Pun, P.B., Lu, J., Moochhala, S., 2009. Involvement of ROS in BBB dysfunction. Free Radic. Res. 43, 348-364.
116. Robberecht, W., 2000. Oxidative stress in amyotrophic lateral sclerosis. J. Neurol. 247 (Suppl. 1), 1-6. (Pubitemid 30182081)
117. Ronaldson, P.T., Demarco, K.M., Sanchez-Covarrubias, L., Solinsky, C.M., Davis, T.P., 2009. Transforming growth factor-beta signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain. J. Cereb. Blood Flow Metab. 29, 1084-1098.
118. Rosen, D.R., et al., 1993. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62. (Pubitemid 23087289)
119. Rosenberg, G.A., 2002a. Matrix metalloproteinases in neuroinflammation. Glia 39, 279-291.
120. Rosenberg, G.A., 2002b. Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 8, 586-595. (Pubitemid 35379453)
121. Rosenberg, G.A., Estrada, E.Y., Dencoff, J.E., 1998. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29, 2189-2195. (Pubitemid 28443538)
122. Rothstein, J.D., 2009. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 65 (Suppl. 1), S3-S9.
123. Rowland, L.P., Shneider, N.A., 2001. Amyotrophic lateral sclerosis. N. Engl. J. Med. 344, 1688-1700.
124. Rubin, L.L., et al., 1991. A cell culture model of the blood-brain barrier. J. Cell Biol. 115, 1725-1735. (Pubitemid 21910012)
125. Rule, R.R., Schuff, N., Miller, R.G., Weiner, M.W., 2010. Gray matter perfusion correlates with disease severity in ALS. Neurology 74, 821-827.
126. Rutka, J.T., Apodaca, G., Stern, R., Rosenblum, M., 1988. The extracellular matrix of the central and peripheral nervous systems: structure and function. J. Neurosurg. 69, 155-170.
127. Saleh, I.A., et al., 2009. Evaluation of humoral immune response in adaptive immunity in ALS patients during disease progression. J. Neuroimmunol. 215, 96-101.
128. Sasaki, A., Nakazato, Y., Ogawa, A., Sugihara, S., 1996. The immunophenotype of perivascular cells in the human brain. Pathol. Int. 46, 15-23.
129. Saunders, N.R., Habgood, M.D., Dziegielewska, K.M., 1999. Barrier mechanisms in the brain, I. Adult brain. Clin. Exp. Pharmacol. Physiol. 26, 11-19.
130. Scherrmann, J.M., 2002. Exchanges through the blood-brain barrier. Ann. Pharm. Fr. 60, 372-379.
131. Schinkel, A.H., et al., 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502. (Pubitemid 24153990)
132. Shapiro, S., Khodalev, O., Bitterman, H., Auslender, R., Lahat, N., 2010. Different activation forms of MMP-2 oppositely affect the fate of endothelial cells. Am. J. Physiol. Cell Physiol. 298, C942-C951.
133. Sobue, K., et al., 1999. Induction of blood-brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors. Neurosci. Res. 35, 155-164.
134. Soon, C.P., et al., 2010. Serum matrix metalloproteinase-9 activity is dysregulated with disease progression in the mutant SOD1 transgenic mice. Neuromuscul. Disord. 20, 260-266.
135. Stamatovic, S.M., Dimitrijevic, O.B., Keep, R.F., Andjelkovic, A.V., 2006. Protein kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability. J. Biol. Chem. 281, 8379-8388.
136. Sternlicht, M.D., Werb, Z., 2001. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17, 463-516.
137. Stewart, P.A., Wiley, M.J., 1981. Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: a study using quail-chick transplantation chimeras. Dev. Biol. 84, 183-192.
138. Strong, M.J., Kesavapany, S., Pant, H.C., 2005. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J. Neuropathol. Exp. Neurol. 64, 649-664.
139. Taraboletti, G., et al., 2002. Shedding of thematrixmetalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am. J. Pathol. 160, 673-680.
140. Tomas-Camardiel, M., et al., 2005. Blood-brain barrier disruption highly induces aquaporin-4 mRNA and protein in perivascular and parenchymal astrocytes: protective effect by estradiol treatment in ovariectomized animals. J. Neurosci. Res. 80, 235-246.
141. Tontsch, U., Bauer, H.C., 1991. Glial cells and neurons induce blood-brain barrier related enzymes in cultured cerebral endothelial cells. Brain Res. 539, 247-253.
142. Van Den Bosch, L., Van Damme, P., Bogaert, E., Robberecht, W., 2006. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1762, 1068-1082.
143. Vangilder, R.L., Rosen, C.L., Barr, T.L., Huber, J.D., 2011. Targeting the neurovascular unit for treatment of neurological disorders. Pharmacol. Ther. 130, 239-247.
144. Verstraete, E., et al., 2010. No evidence of microbleeds in ALS patients at 7 Tesla MRI. Amyotroph. Lateral Scler. 11, 555-557.
145. Vos, C.M.P., et al., 2005. Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol. Dis. 20, 953-960.
146. Wallace, J.A., et al., 2002. Tissue inhibitor of metalloproteinase-3 is associated with neuronal death in reperfusion injury. J. Cereb. Blood Flow Metab. 22, 1303-1310.
147. Wang, Y.Y., Lui, P.C., Li, J.Y., 2009. Receptor-mediated therapeutic transport across the blood-brain barrier. Immunotherapy 1, 983-993.
148. Washington, R., et al., 1994. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann. Neurol. 35, 89-97.
149. Wolburg, H., Wolburg-Buchholz, K., Engelhardt, B., 2005. Diapedesis of mononuclear cells across cerebral venules during experimental autoimmune encephalomyelitis leaves tight junctions intact. Acta Neuropathol. 109, 181-190. (Pubitemid 40468387)
150. Wolburg, H., Noell, S., Mack, A., Wolburg-Buchholz, K., Fallier-Becker, P., 2009a. Brain endothelial cells and the glio-vascular complex. Cell Tissue Res. 335, 75-96.
151. Wolburg, H., Noell, S., Wolburg-Buchholz, K., Mack, A., Fallier-Becker, P., 2009b. Agrin, aquaporin-4, and astrocyte polarity as an important feature of the blood-brain barrier. Neuroscientist 15, 180-193.
152. Wolburg-Buchholz, K., et al., 2009. Loss of astrocyte polarity marks blood-brain barrier impairment during experimental autoimmune encephalomyelitis. Acta Neuropathol. 118, 219-233.
153. Woo, M.S., Park, J.S., Choi, I.Y., Kim, W.K., Kim, H.S., 2008. Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. J. Neurochem. 106, 770-780.
154. Yamauchi, A., et al., 2007. An inhibitory role of nitric oxide in the dynamic regulation of the blood-brain barrier function. Cell. Mol. Neurobiol. 27, 263-270.
155. Yeagle, P., 1987. Transport. In: Yeagle, P. (Ed.), The Membranes of Cells. Academic Press Inc., Orlando, F. L., pp. 191-215.
156. Yoshihara, T., et al., 2002. Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenicmousemodel of familial amyotrophic lateral sclerosis. J. Neurochem. 80, 158-167. (Pubitemid 34614588)
157. Zamboni, P., et al., 2009a. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 80, 392-399.
158. Zamboni, P., et al., 2009b. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J. Vasc. Surg. 50, 1348-1358.
159. Zamboni, P., et al., 2009c. The severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis is related to altered cerebrospinal fluid dynamics. Funct. Neurol. 24, 133-138.
160. Zhong, Z., et al., 2008. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat. Neurosci. 11, 420-422.
161. Zhou, J., et al., 2008. Altered blood-brain barrier integrity in adult aquaporin-4 knockout mice. Neuroreport 19, 1-5. (Pubitemid 351339611)
162. Zhu, H.J., Liu, G.Q., 2004. Glutamate up-regulates P-glycoprotein expression in rat brain microvessel endothelial cells by an NMDA receptor-mediated mechanism. Life Sci. 75, 1313-1322.